2,2-二甲基-3-(苯基硫代)丙酸 | 27943-35-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2,2-二甲基-3-(苯基硫代)丙酸
• 英文名称: 2,2-dimethyl-3-(phenylthio)propanoic acid
• 英文别名: 2,2-dimethyl-3-(phenylthio)propionic acid；2,2-dimethyl-3-phenylsulfanyl-propionic acid；3-Phenylmercapto-2,2-dimethyl-propionsaeure；2,2-Dimethyl-3-phenylthio-propionsaeure；2,2-dimethyl-3-phenylsulfanylpropanoic acid
• CAS: 27943-35-7
• 化学式: C₁₁H₁₄O₂S
• 分子量: 210.297
• InChiKey: WZNNKIDVSDAOEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-二甲基-3-(苯基硫代)丙酸 在 氯化亚砜 作用下， 生成 N-2,2-trimethyl-3-(phenylthio)-propionamide
  参考文献：
  名称：

  Easton, Christopher J., Journal of the Chemical Society. Perkin transactions I, 1985, p. 153 - 158

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(quinolin-8-yl)pivalamide 在 sodium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium hydroxide 、 nickel dibromide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 2,2-二甲基-3-(苯基硫代)丙酸
  参考文献：
  名称：

  Nickel-Catalyzed Direct Thiolation of C(sp³)–H Bonds in Aliphatic Amides

  摘要：

  Nickel-catalyzed thiolation of the inactivated methyl C(sp(3))-H bonds of aliphatic amides with disulfide is described. It is a novel strategy for the synthesis of thioethers with the ultimate goal of generating thioether carboxylic acids with various functional groups.

  DOI：

  10.1021/acs.orglett.5b00706

文献信息

• Formation of β-lactams from 3-phenylthiopropionamide derivatives
  作者：Athelstan L.J. Beckwith、Christopher J. Easton

  DOI：10.1016/s0040-4020(01)90907-x

  日期：1983.1

  neither β-lactams nor benzoates can be obtained from the thiazepines (23a, 23b) Dimethyl disulfide is benzoyloxylated on treatment with t-butyl perbenzoate. The relevance of these results to penicillin biosynthesis is discussed.

  取代的3-苯基硫代丙酰胺（10a）与过氧化二叔丁基的铜催化反应通过α-硫代烷基（11a）的氧化环化反应生成β-内酰胺（14a）。在丙酰胺（的类似反应10A，10B）与叔丁基过苯甲酸酯给予苯甲酸酯（15，17），其可容易地转化成β内酰胺（14A，14B），但既不β内酰胺也不苯甲酸酯可以从获得硫氮平（23a，23b在用过苯甲酸叔丁酯处理时，二甲基二硫化物被苯甲酰氧基化。讨论了这些结果与青霉素生物合成的相关性。
• Amelioration of cataracts, macular degeneration and other ophthalmic diseases
  申请人：Matier L. William

  公开号：US20050131025A1

  公开（公告）日：2005-06-16

  Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  本发明涉及可用于阻止白内障、老视、黄斑变性和其他视网膜病变、青光眼、葡萄膜炎以及各种角膜疾病的眼科可接受的组合物。该组合物还可用作预防性治疗，以预防或延迟年龄相关的眼部疾病的发展，包括白内障、老视、青光眼和黄斑变性。该组合物包括一种药用可接受的载体或稀释剂和至少一种具有以下式子的化合物：其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；而R1和R2一起取代，或R3和R4一起取代，或两者都可以是环烷基；R5为H、OH或C1到C6烷基；R6为C1到C6烷基、烯基、炔基或取代的烷基或烯基；R7为C1到C6烷基、烯基、炔基或取代的烷基或烯基，或者R6和R7，或者R5、R6和R7一起形成一个具有3到7个原子的环烷或杂环。
• Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
  申请人：Matier William L.

  公开号：US20130131052A1

  公开（公告）日：2013-05-23

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  眼科可接受的组合物，用于阻止白内障或黄斑变性的发展，包括一种药学可接受的载体或稀释剂和一种具有以下化学式的化合物：其中R1和R2分别为H或C1到C3烷基；R3和R4分别为C1到C3烷基；且其中R1和R2，一起取或R3和R4，一起取或两者都可以是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基，或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的碳环或杂环。
• ORGANIC COMPOUNDS
  申请人：Adams Christopher

  公开号：US20100048562A1

  公开（公告）日：2010-02-25

  The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11 beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种公式I的化合物：该化合物是醛固酮合成酶（CYP11B2）和/或11β-羟化酶（CYP11B1）和/或芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶、芳香化酶或CYP11B1介导的疾病或疾病。因此，公式I的化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。最后，本发明还提供了一种制药组合物。
• Organic compounds
  申请人：Adams Christopher

  公开号：US08436035B2

  公开（公告）日：2013-05-07

  The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11 beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种I式化合物：所述化合物是醛固酮合成酶（CYP11B2）和/或11-β-羟化酶（CYP11B1）和/或芳香化酶的抑制剂，因此可用于治疗由醛固酮合成酶、芳香化酶或CYP11B1介导的疾病或疾患。因此，I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾衰竭，特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。最后，本发明还提供了一种制药组合物。